Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Elquis Castillo (NPI 1609890474)

Field	Value
Entity Type	Individual
Organization	Elquis Castillo
Address	705 Goodyear Ave
City	Gadsden
State	AL
ZIP	35903
Taxonomy	Medical Oncology Physician
NPI Enumerated	July 26, 2006

Payer Source	Total Paid
Medicare	$2.5M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused practice: lifetime Medicare revenue is $2.5M and there is no Medicaid billing on file, so payer mix is essentially single-payer Medicare. The NPI was enumerated on 2006-07-26 (~20 years ago), indicating long-tenured enrollment in the Medicare program.

Revenue is highly concentrated in a small number of drug codes: the top 3 Medicare codes by revenue account for 76.3% of this provider's total Medicare revenue, driven by J9271 (52.7%), J1568 (17.5%), and J1437 (6.1%). That concentration signals the practice’s financial dependence on a few high-revenue infusion products rather than a broad, even revenue distribution across many services.

The code mix and volume profile identify an infusion-centric medical oncology operation: high-revenue use of J9271 (pembrolizumab) combined with chemotherapy administration codes such as 96413 (ranks #200 of 7514, 97th percentile; notably above typical national volume) and 96402 (ranks #73 of 4765, 98th percentile; extreme outlier) point to routine delivery of immunotherapy and systemic cancer treatments in an outpatient infusion setting. Frequent use of infusion administration codes (e.g., 96365) supports an on-site infusion workflow.

On competitive standing for specific high-revenue drugs, the provider is a clear national high-volume participant for its top immunotherapy and supportive drugs: J9271 ranks #112 of 1841 providers nationally (94th percentile; notably above typical national volume) and J1568 ranks #17 of 381 providers nationally (96th percentile; typical, unremarkable volume). These ranks indicate the provider is well above the median national volume for pembrolizumab and among the higher-volume users of IVIG products.

Encounter complexity and documented office intensity are elevated: E/M codes 99214 (789 claims) and 99215 (456 claims) rank in the 96th and 98th percentiles respectively (99215 labeled an extreme outlier), indicating a high proportion of moderate-to-high complexity visits consistent with oncology follow-up and management. The presence of many higher-level E/M visits reinforces the clinical intensity that accompanies the infusion and chemotherapy mix.

Supportive oncology services and ancillary therapeutics are also prominent: drugs and products such as J1437 (ferric derisomaltose, ranks #36 of 581, 94th percentile; notably above typical national volume), J9395 (fulvestrant, ranks #14 of 227, 94th percentile; notably above typical national volume), and J3489 (zoledronic acid, ranks #37 of 3032, 99th percentile; extreme outlier) show the practice delivers a broad set of supportive and endocrine therapies in addition to primary cancer treatments. Epoetin alfa (J0885) and denosumab (J0897) also appear in the top codes, reflecting anemia and bone-health management in oncology care.

Operational footprint is consistent with an on-site infusion center supported by diagnostics and specimen collection: high percentiles for infusion-related procedure codes (96365 ranks #305 of 8873, 97th percentile; 96375 ranks #330 of 5191, 94th percentile) plus lab draw/CBC codes (85025 ranks #642 of 32833, 98th percentile; 36415 ranks #1497 of 86467, 98th percentile) suggest integrated infusion and phlebotomy capacity to support frequent infusion visits. This combination supports a workflow optimized for repeated IV administrations and same-day monitoring.

From a revenue and strategic perspective, dependence on a single high-cost biologic is notable: J9271 alone represents $1.3M and 52.7% of the provider's Medicare revenue, so changes in utilization, reimbursement, or formularies for that agent would disproportionately affect overall Medicare revenue. Coupled with no Medicaid billing on file, there is limited payer diversification, which may concentrate financial exposure to Medicare policy and drug-pricing trends.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

47 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	30,800	$40	$1.3M
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	13,450	$30	$430.5K
J1437	Injection, ferric derisomaltose, 10 mg	9,300	$20	$148.8K
J0897	Injection, denosumab, 1 mg	7,080	$20	$134.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	770	$90	$69.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	790	$90	$67.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	460	$130	$57K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	9,440	$10	$56.6K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	340	$100	$32.6K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	490	$50	$25K

Showing 1–10 of 47

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 47 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Elquis Castillo — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

47 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	30	19,900	$40	$827.2K
J1568	7	30	5,180	$30	$316.2K
J0897	49	200	3,120	$20	$97.7K
J1437	2	40	3,000	$20	$59.1K
Q5108	6	10	370	$100	$38.1K
J0885	1	10	3,660	$10	$32.3K
96413	4	150	150	$90	$20.2K
99214	320	7,330	120	$80	$16.8K
99233	1,712	1,860	80	$90	$13.4K
99232	1,616	2,530	100	$60	$13.3K

Showing 1–10 of 47

Related Providers

Other providers that share a Tax Identification Number (TIN) with Elquis Castillo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Khaleel Ashraf	AL	Hematology & Oncology Physician	$1.4M	$0
Allen Yeilding	AL	Hematology & Oncology Physician	$980.4K	$0
David Mooney	AL	Hematology & Oncology Physician	$303.4K	$0
Alejandro Garcia	AL	Hematology & Oncology Physician	$230.4K	$0
Shawnta Anakwah	AL	Hematology & Oncology Physician	$213K	$0
Jonathan Bridges	AL	Hematology & Oncology Physician	$204.6K	$0
Elliott Saltz	AL	Family Medicine Physician	$94.9K	$0

Nearby Providers

Other providers in the same ZIP code as Elquis Castillo, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Quality Of Life Health Services Inc	AL	Community Health Clinic/Center	$0	$6.6M
Children And Teen Dental Group Of Alabama	AL	Pediatric Dentistry	$0	$5.2M
Gadsden Regional Medical Center LLC	AL	General Acute Care Hospital	$0	$4.1M
Oral Surgery Associates, PC	AL	Oral and Maxillofacial Surgery (Dentist)	$0	$1.2M
Womens Health Partners LLC	AL	Obstetrics & Gynecology Physician	$0	$1.1M
Omi Of Gadsden Petct LLC	AL	Diagnostic Radiology Physician	$910.5K	$0
Farah Al Khitan	AL	Interventional Cardiology Physician	$839.9K	$0
Krishna Chaitanya Keri	AL	Nephrology Physician	$339.1K	$0
Rameshkumar Athippalayam Chellamuthu	AL	Nephrology Physician	$272.6K	$0
James Smith	AL	Orthopaedic Surgery Physician	$251.8K	$0

Elquis Castillo — Billing Profile & Reimbursement Data

Sign up for Elquis Castillo — Billing Profile & Reimbursement Data policy alerts

Elquis Castillo — Billing Profile & Reimbursement Data

Sign up for Elquis Castillo — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References